Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014
Key takeaways of recent quarter & conference call highlights
This strategic collaboration will enable continued innovation in cancer care
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
The platform has seen an overall growth of 84% in the number of people seeking consultations for skin-related issues
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
Subscribe To Our Newsletter & Stay Updated
